- Home
- DYAI vs INKT Comparison
DYAI vs INKT Comparison
Compare DYAI & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DYAI
- INKT
- Stock Information
- Founded
- DYAI 1979
- INKT 2017
- Country
- DYAI United States
- INKT United States
- Employees
- DYAI N/A
- INKT N/A
- Industry
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- INKT Medicinal Chemicals and Botanical Products
- Sector
- DYAI Health Care
- INKT Health Care
- Exchange
- DYAI Nasdaq
- INKT Nasdaq
- Market Cap
- DYAI 28.3M
- INKT 28.8M
- IPO Year
- DYAI 2004
- INKT 2021
- Fundamental
- Price
- DYAI $0.98
- INKT $62.86
- Analyst Decision
- DYAI Strong Buy
- INKT Strong Buy
- Analyst Count
- DYAI 1
- INKT 2
- Target Price
- DYAI $6.00
- INKT $37.50
- AVG Volume (30 Days)
- DYAI 63.9K
- INKT 2.4M
- Earning Date
- DYAI 08-12-2025
- INKT 08-12-2025
- Dividend Yield
- DYAI N/A
- INKT N/A
- EPS Growth
- DYAI N/A
- INKT N/A
- EPS
- DYAI N/A
- INKT N/A
- Revenue
- DYAI $3,554,344.00
- INKT N/A
- Revenue This Year
- DYAI $22.56
- INKT N/A
- Revenue Next Year
- DYAI $30.95
- INKT N/A
- P/E Ratio
- DYAI N/A
- INKT N/A
- Revenue Growth
- DYAI 57.59
- INKT N/A
- 52 Week Low
- DYAI $0.91
- INKT $4.56
- 52 Week High
- DYAI $2.20
- INKT $76.00
- Technical
- Relative Strength Index (RSI)
- DYAI 53.08
- INKT 57.39
- Support Level
- DYAI $0.91
- INKT $6.80
- Resistance Level
- DYAI $0.99
- INKT $7.88
- Average True Range (ATR)
- DYAI 0.06
- INKT 0.40
- MACD
- DYAI 0.01
- INKT 0.02
- Stochastic Oscillator
- DYAI 59.93
- INKT 58.86
About DYAI Dyadic International Inc.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.